ArticlePharmacology research & perspectives2026
Securidaca inappendiculata Extract Mitigates Joint Damage in Collagen-Induced Arthritis Rats Through Modulation of the SIRT1/HIF-1α/Glycolysis Pathway.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Securidaca inappendiculata (SI) Hassk. is a traditional Chinese herbal medicine commonly used in Southern China for the treatment of rheumatoid arthritis (RA). However, its exact mechanism of action remains unclear. In this study, we evaluated the therapeutic effects of the SI-derived compound 1,7-dihydroxy-3,4-dimethoxyxanthone (XAN) in a collagen-induced arthritis (CIA) rat model by measuring paw thickness, joint morphology, and histopathological changes. In vitro, cytotoxicity of XAN on RAW 264.7 macrophages was assessed using the Cell Counting Kit-8 (CCK-8) assay. Additional experiments, including real-time PCR, immunofluorescence, glycolytic metabolism analysis, Western blotting, and dual-luciferase reporter assays, were conducted to investigate the mechanisms underlying the anti-inflammatory effects of XAN. Results showed that XAN significantly alleviated arthritis severity in CIA rats. In RAW 264.7 cells, lipopolysaccharide (LPS) enhanced glycolysis and upregulated NAMPT and HIF-1α expression, whereas SIRT1 levels were reduced. XAN treatment reversed these effects by suppressing glycolysis in LPS-induced macrophages, indicating that its anti-inflammatory activity involves modulation of cellular energy metabolism. Further mechanistic studies revealed that XAN attenuates inflammation by regulating the SIRT1/HIF-1α/glycolysis signaling axis in macrophages. These findings underscore the role of energy metabolism in macrophage polarization and suggest that targeting this pathway may represent a promising therapeutic strategy for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.